EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY-NC 4.0

Baseline characteristics and feasibility of clinical outcome measures in CDKL5 deficiency disorder: The CANDID observational study

Xavier Liogier d'Ardhuy iD, CANDID Partners, Tricia Cimms, Kristina Lindsten iD, Marco Rizzo iD, Alison Skrinar iD, Peter St Wecker iD, Ana Mingorance iD, Orrin Devinsky iD

Epilepsia · 2026-04 · 67 (4) · 1703-1721

DOI: 10.1002/epi.70095 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Epilepsia, online erschienen am 13.01.2026. Verfasst von Xavier Liogier d'Ardhuy und 8 weiteren Autor:innen. Beteiligte Einrichtung: Loulou Foundation, London, UK. Hauptthemen laut MEDLINE: Epileptic Syndromes, Spasms, Infantile, Outcome Assessment, Health Care. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: PTC Therapeutics, Amicus Therapeutics, UCB.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

CDKL5 deficiency disorder (CDD) is a rare X‐linked developmental and epileptic encephalopathy caused by loss‐of‐function variants in the CDKL5 gene. Preclinical experiments using enzyme replacement or gene therapies show promise and could be transformative therapies. This precompetitive consortium sought to harmonize nonseizure clinical endpoint selection for efficacy trials. Clinical Assessment of Neurodevelopmental Measures in CDD (CANDID) is an ongoing study evaluating the feasibility and suitability of neurocognitive tests and functioning scales in CDD patients.

Methods

CANDID is a 3‐year, longitudinal, noninterventional global study involving children and adults with CDD. On‐site and remote visits include clinical, behavioral, developmental, and quality of life assessments.

Results

We enrolled 112 patients (111 included in analyses); mean age = 8.3 years (range 16 seizures; six were seizure‐free. Median seizure onset was at 1.5 months (range = 0–66). Patients used an average of 2.6 antiseizure medications at baseline. The most frequent comorbidities included gastrointestinal hypomotility, muscle tone abnormalities, and sleep disorders. Gross Motor Function Measure‐88 (GMFM‐88) scores indicated a floor effect in crawling, standing, and walking across all ages. Vineland‐3 and Bayley‐4 scores could be derived in most, with receptive language, interpersonal relationships, and fine and gross motor scores increasing with age. Bruni sleep questionnaire identified sleep initiation, sleep–awake transition, and excessive somnolence as the most disrupted components across all age groups. The mean Quality of Life Inventory–Disability total scores ranged from 53% to 64%, the independence domain being the most impacted. Significance The scales in the CANDID study capture disease‐related deficits and phenotype variability in CDD. Floor effects in subdomains aligned with disease severity. The GMFM‐88 lacks granularity, and its operational limitations make it unsuitable for CDD trials. Baseline analyses demonstrate the feasibility and potential value of most selected scales, supporting their use in optimizing trial design and endpoint selection for future CDD clinical trials.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Epileptic SyndromesSpasms, InfantileOutcome Assessment, Health CareHumansFemaleChild, PreschoolChildInfantMaleAdolescentAdultFeasibility StudiesYoung AdultLongitudinal StudiesQuality of LifeProtein Serine-Threonine KinasesAnticonvulsantsNeuropsychological Tests

Stichwörter der Autor:innen

CANDIDCDDCDKL5clinical trial readinessnatural history study

Substanzen

Protein Serine-Threonine KinasesAnticonvulsants

Autor:innen und Institutionen

  • Loulou Foundation, London, UK.
  • Ultragenyx Pharmaceutical, Novato, California, USA.
  • Immedica Pharma, Stockholm, Sweden.
  • Biogen, Cambridge, Massachusetts, USA.
  • UCB Biosciences, Morrisville, North Carolina, USA.
  • Department of Neurology, NYU Grossman School of Medicine, New York, New York, USA.

ORCID-Profile: Xavier Liogier d'Ardhuy, Kristina Lindsten, Marco Rizzo, Alison Skrinar, Peter St Wecker, Ana Mingorance, Orrin Devinsky

Förderung

  • PTC Therapeutics
  • Amicus Therapeutics
  • UCB
  • Marinus Pharmaceuticals
  • Ultragenyx Pharmaceutical
  • Biogen
  • Elaaj Bio

Zitieren

APA

Liogier d'Ardhuy, X., CANDID Partners, Cimms, T., Lindsten, K., Rizzo, M., Skrinar, A., St Wecker, P., Mingorance, A., & Devinsky, O. (2026). Baseline characteristics and feasibility of clinical outcome measures in CDKL5 deficiency disorder: The CANDID observational study. Epilepsia, 67(4), 1703-1721. https://doi.org/10.1002/epi.70095

Vancouver

Liogier d'Ardhuy X, CANDID Partners, Cimms T, Lindsten K, Rizzo M, Skrinar A, et al. Baseline characteristics and feasibility of clinical outcome measures in CDKL5 deficiency disorder: The CANDID observational study. Epilepsia. 2026;67(4):1703-1721. doi:10.1002/epi.70095

BibTeX
@article{LiogierdArdhuy2026,
  author = {Liogier d'Ardhuy, Xavier and CANDID Partners, CANDID Partners and Cimms, Tricia and Lindsten, Kristina and Rizzo, Marco and Skrinar, Alison and St Wecker, Peter and Mingorance, Ana and Devinsky, Orrin},
  title = {Baseline characteristics and feasibility of clinical outcome measures in CDKL5 deficiency disorder: The CANDID observational study},
  journal = {Epilepsia},
  year = {2026},
  volume = {67},
  number = {4},
  pages = {1703--1721},
  doi = {10.1002/epi.70095}
}
Kostenlos starten →